Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 14/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11935405 | 1.00 | OPRM1 (0.41) | OPRM1OPRL1JAK1SLC18A3JAK2 | |
| SCHEMBL11941110 | 0.84 | OPRL1 (0.46) | OPRM1OPRL1JAK1SLC18A3CCR1 | |
| SCHEMBL11935273 | 0.84 | OPRL1 (0.46) | OPRM1OPRL1JAK1SLC18A3CCR1 | |
| SCHEMBL13565102 | 0.83 | NPY5R (0.41) | JAK1CCR1 | |
| SCHEMBL17090383 | 0.83 | NPY5R (0.41) | JAK1CCR1 | |
| SCHEMBL13113908 | 0.79 | KDM4E (0.41) | OPRM1OPRL1JAK1SLC18A3DRD2 | |
| SCHEMBL11935922 | 0.78 | OPRL1 (0.39) | OPRL1JAK1DRD2DRD4DRD3 | |
| SCHEMBL11935770 | 0.78 | DRD2 (0.43) | JAK1DRD2DRD4DRD3CCR1 | |
| SCHEMBL13113907 | 0.75 | OPRM1 (0.39) | OPRM1OPRL1JAK1SLC18A3JAK2 | |
| SCHEMBL11935086 | 0.72 | ERBB2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | NPY5R, NPY1R, NPY2R | OPRM1 56/4885OPRL1 23/4885JAK1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.